May 5, 2018 09:43 AM EDT

With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine

John Carroll

Editor & Founder

J&J researchers rolled out data from the first two pivotal trials of their anti-depression drug esketamine today, blazing a trail that they say leads straight …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine

John Carroll

Editor & Founder

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

With hits and miss­es in first piv­otal tri­als, J&J con­fi­dent­ly maps a path to the FDA with its ma­jor de­pres­sion med es­ke­t­a­mine

Editor & Founder

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine